We're thrilled JMI Labs is part of Element, and we continue to provide critical antimicrobial surveillance studies through the SENTRY program. Your study will benefit from our more than two decades of extensive experience performing surveillance studies for new drug development and post-marketing monitoring of approved drugs. Every year, we receive around 40,000 clinical isolates of bacteria and fungi through a network of more than 150 medical centers from more than 35 countries worldwide. Click here to view the public data set.

Antimicrobial surveillance services

We use a consortium-based participation model, which allows for inclusion at a complete or partial level geographic, pathogen or indication specific.

  • Isolates are consecutively collected by site of infections
  • Susceptibility testing by reference broth microdilution methods
  • CLSI and EUCAST breakpoints
  • Real-time data monitoring for trend analysis of antimicrobial resistance patterns
  • Resistance mechanism detection by whole genome sequencing

Know more about SENTRY

Expand the box below for answers to the most frequently asked questions about the SENTRY Antimicrobial Surveillance Program. Scroll down for links to access SENTRY. Interested in conducting an antimicrobial surveillance study? Fill out a short form to request information

What is SENTRY?

The SENTRY Antimicrobial Surveillance Program was established in 1997 and now is one of the longest running antimicrobial surveillance programs in the world. SENTRY monitors worldwide pathogens and the changes in resistance patterns over time through centralized testing and utilizing reference susceptibility methods. SENTRY focuses on recruiting medical centers and hospital sites to participate each calendar in submitting organisms through a prevalence-based approach across a number of different types of infections. The study design collects clinical isolates under the following objectives: bloodstream, skin and soft tissue, respiratory, urinary tract, pathogens from patients hospitalized with pneumonia, intra-abdominal and invasive fungal infections. This prevalence based-approach requirement is critically important to measure the resistance patterns that guide local therapy, alert the scientific community of potential growing threats, and to steer antimicrobial research and development.

How can hospitals participate?

We recruit sites based on geography. The majority of our sites are in the United States and Europe, but we have a significant presence in Latin America, parts of Asia, and the Western Pacific. Fill out a short form to request more information about enrolling your hospital.

Can unique surveillance requirements be accommodated?

Clients that would like a more tailored surveillance program, such as wanting a unique set of sites to be recruited or certain set of organisms within their approved label of indicated species, can still participate in SENTRY. We would employ a hybrid approach. Element will take your preferred study parameters and create a special objective for SENTRY, achieving a unique program for you within our established support network.

How can my drug be incorporated in the program? 

New compounds and other agents can be integrated into the SENTRY platform by establishing agreements and transferring compounds at the beginning of the calendar year. Element bears the costs of the entire program. Each client only contracts for their desired surveillance data, such as geography or specific types of infections or pathogens, resulting in lower costs due to a shared platform approach. Ready to start the conversation? Fill out a short form and a member of our team will be in touch with you promptly.

Our team of over 9,000 Engaged Experts in North America, Europe, The Middle East, Australia, Asia and Africa are ready to help you.